Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments close on Thursday 24 September at 4:30pm because of system upgrades. We expect to open them again on Friday 25 September at 8am the latest.

Samsjuklighet vid bipolär sjukdom: Validering av risk/bio-markörer för bättre prevention och behandling - BIPCOM

Reference number
Coordinator Örebro universitet - Örebro universitet Inst f medicinska vetenskaper
Funding from Vinnova SEK 2 970 764
Project duration November 2022 - July 2026
Status Completed
Venture European partnership for Personalised Medicine
Call ERA PerMed Joint Transnational Call 2022: Personalised Prevention

Important results from the project

The overall objective of the project has been achieved. The project has contributed to increased knowledge about bipolar disorder, its prevalence, disease course and factors associated with different clinical outcomes. By using extensive population-based data and epidemiological and statistical methods, the project has enabled in-depth analyses of issues relevant to both research and clinical activities.

Expected long term effects

In the longer term, the project´s results are expected to contribute to a better understanding of bipolar disorder and the factors that influence the development and clinical course of the disease. The results may help identify areas where future research and clinical efforts can be directed more effectively.

Approach and implementation

The project was planned as a population-based epidemiological research project focusing on bipolar disorder. The work included data collection and processing, development and implementation of statistical analyses, and interpretation and scientific reporting of the results.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 25 August 2026

Reference number 2022-00541